Multimedialna platforma wiedzy medycznej Internetowa Księgarnia Medyczna Kalendarium Konferencji
Clinical Diabetology
MENU
Shortcuts Submit an article Author Guidelines Ahead Of Print Reviewers 2022

open access

Vol 12, No 1 (2023)
Research paper
Submitted: 2022-07-20
Accepted: 2022-09-25
Published online: 2022-12-27
View PDF Download PDF file
Get Citation

Association of Low Placental Growth Factor Gene Expression with Maternal and Neonatal Outcomes in Type 1 Diabetes: A Single Center, Cross-Sectional Study

Rafał Iciek1, Paweł Gutaj1, Sara Królik1, Grażyna Kurzawińska2, Anna Bogacz3, Agnieszka Seremak-Mrozikiewicz2, Przemysław Mikołajczak45, Jacek Brązert1, Ewa Wender-Ożegowska1
DOI: 10.5603/DK.a2022.0056
·
CD 2023;12(1):38-44.
Affiliations
  1. Department of Reproduction, Poznań University of Medical Sciences, Poznań, Poland
  2. Department of Perinatology and Women’s Diseases, Poznań University of Medical Sciences, Poznań, Poland
  3. Department of Stem Cells and Regenerative Medicine, Institute of Natural Fibers and Medicinal Plants, Poznań, Poland
  4. Chair and Institute of Pharmacology, Poznań University of Medical Sciences, Poznań, Poland
  5. Chair and Institute of Clinical Pharmacy and Biopharmacy, Poznań University of Medical Sciences, Poznań, Poland

open access

Vol 12, No 1 (2023)
Original articles
Submitted: 2022-07-20
Accepted: 2022-09-25
Published online: 2022-12-27

Abstract

Objective: The placental growth factor (PlGF) plays a crucial role in early and late pregnancy placental development. Pregestational type 1 diabetes (T1D) is a pregnancy complication that may lead to serious fetomaternal complications. Our study analyzed the association between placental PlGF mRNA expression and metabolic control, fetal weight and development in women with T1D.

Materials and methods: A cross-sectional study on 65 pregnant women with T1D in singleton pregnancies admitted to the tertiary-level perinatal care unit. The study examined associations between the placental mRNA-PlGF gene expression measured with quantitative real-time PC and markers of maternal metabolism in the third trimester. The expression was also compared across maternal subgroups stratified according to the birth weight (small- vs. appropriate- vs. large-for-gestational age; SGA, AGA, LGA, respectively) and the following neonatal outcomes: mode of delivery, Apgar score and pH in the umbilical vessels.

Results: Placental PlGF mRNA expression was significantly lower in SGA than in AGA and LGA patients (0.60 ± 0.34 vs. 0.63 ± 0.54 vs. 1.02 ± 0.15, respectively, p < 0.05). In the SGA group, the expression of the PlGF-mRNA correlated positively with maternal 3rd trimester BMI (r = 0.49, p = 0.04), pH and BE cord blood values, and maternal 3rd trimester mean BP. There was no correlation between 3rd-trimester glycated hemoglobin and mean blood glucose levels (MBG) and PlGF expression.

Conclusions: Our data suggest that lower PlGF mRNA expression may predict neonatal outcomes in women with T1D giving birth to SGA newborns.

Abstract

Objective: The placental growth factor (PlGF) plays a crucial role in early and late pregnancy placental development. Pregestational type 1 diabetes (T1D) is a pregnancy complication that may lead to serious fetomaternal complications. Our study analyzed the association between placental PlGF mRNA expression and metabolic control, fetal weight and development in women with T1D.

Materials and methods: A cross-sectional study on 65 pregnant women with T1D in singleton pregnancies admitted to the tertiary-level perinatal care unit. The study examined associations between the placental mRNA-PlGF gene expression measured with quantitative real-time PC and markers of maternal metabolism in the third trimester. The expression was also compared across maternal subgroups stratified according to the birth weight (small- vs. appropriate- vs. large-for-gestational age; SGA, AGA, LGA, respectively) and the following neonatal outcomes: mode of delivery, Apgar score and pH in the umbilical vessels.

Results: Placental PlGF mRNA expression was significantly lower in SGA than in AGA and LGA patients (0.60 ± 0.34 vs. 0.63 ± 0.54 vs. 1.02 ± 0.15, respectively, p < 0.05). In the SGA group, the expression of the PlGF-mRNA correlated positively with maternal 3rd trimester BMI (r = 0.49, p = 0.04), pH and BE cord blood values, and maternal 3rd trimester mean BP. There was no correlation between 3rd-trimester glycated hemoglobin and mean blood glucose levels (MBG) and PlGF expression.

Conclusions: Our data suggest that lower PlGF mRNA expression may predict neonatal outcomes in women with T1D giving birth to SGA newborns.

Full Text:

View PDF Download PDF file
Get Citation

Keywords

diabetes, pregnancy, glycemia, placenta, growth factor, fetal weight

About this article
Title

Association of Low Placental Growth Factor Gene Expression with Maternal and Neonatal Outcomes in Type 1 Diabetes: A Single Center, Cross-Sectional Study

Journal

Clinical Diabetology

Issue

Vol 12, No 1 (2023)

Article type

Research paper

Pages

38-44

Published online

2022-12-27

Page views

1166

Article views/downloads

107

DOI

10.5603/DK.a2022.0056

Bibliographic record

CD 2023;12(1):38-44.

Keywords

diabetes
pregnancy
glycemia
placenta
growth factor
fetal weight

Authors

Rafał Iciek
Paweł Gutaj
Sara Królik
Grażyna Kurzawińska
Anna Bogacz
Agnieszka Seremak-Mrozikiewicz
Przemysław Mikołajczak
Jacek Brązert
Ewa Wender-Ożegowska

References (34)
  1. Entrez Gene: PGF placental growth factor, vascular endothelial growth factor-related protein.
  2. Chau K, Hennessy A, Makris A. Placental growth factor and pre-eclampsia. J Hum Hypertens. 2017; 31(12): 782–786.
    CrossRefPubMed
  3. Maglione D, Guerriero V, Viglietto G, et al. Two alternative mRNAs coding for the angiogenic factor, placenta growth factor (PlGF), are transcribed from a single gene of chromosome 14. Oncogene. 1993; 8(4): 925–931.
    PubMed
  4. Khalil A, Muttukrishna S, Harrington K, et al. Effect of antihypertensive therapy with alpha methyldopa on levels of angiogenic factors in pregnancies with hypertensive disorders. PLoS One. 2008; 3(7): e2766.
    CrossRefPubMed
  5. Lecarpentier É, Vieillefosse S, Haddad B, et al. Placental growth factor (PlGF) and sFlt-1 during pregnancy: physiology, assay and interest in preeclampsia. Ann Biol Clin (Paris). 2016; 74(3): 259–267.
    CrossRefPubMed
  6. Khurana R, Moons L, Shafi S, et al. Placental growth factor promotes atherosclerotic intimal thickening and macrophage accumulation. Circulation. 2005; 111(21): 2828–2836.
    CrossRefPubMed
  7. Shibuya M, Shibuya M, Claesson-Welsh L, et al. Vascular endothelial growth factor-dependent and -independent regulation of angiogenesis. BMB Rep. 2008; 41(4): 278–286.
    CrossRefPubMed
  8. Joó JG, Rigó J, Börzsönyi B, et al. Placental gene expression of the placental growth factor (PlGF) in intrauterine growth restriction. J Matern Fetal Neonatal Med. 2017; 30(12): 1471–1475.
    CrossRefPubMed
  9. Dover N, Gulerman HC, Celen S, et al. Placental growth factor: as an early second trimester predictive marker for preeclampsia in normal and high-risk pregnancies in a Turkish population. J Obstet Gynaecol India. 2013; 63(3): 158–163.
    CrossRefPubMed
  10. Ukah UV, Hutcheon JA, Payne B, et al. Prediction of adverse maternal outcomes from pre-eclampsia and other hypertensive disorders of pregnancy: a systematic review. Pregnancy Hypertens. 2018; 11: 115–123.
    CrossRefPubMed
  11. Iciek R, Wender-Ożegowska E, Mikolajczak P, et al. Placental vascular endothelial growth factor expression in pregnancies complicated by type 1 diabetes. J Physiol Pharmacol. 2014; 65(4): 577–583.
    PubMed
  12. Wender-Ożegowska E, Bomba-Opoń D, Brązert J, et al. Sekcja. Standardy skiego Towarzystwa ologicznego postępowania u kobiet z cukrzycą. Ginek Pol. 2011; 82(6): 474–479.
  13. Ringholm L, Mathiesen ER, Kelstrup L, et al. Managing type 1 diabetes mellitus in pregnancy--from planning to breastfeeding. Nat Rev Endocrinol. 2012; 8(11): 659–667.
    CrossRefPubMed
  14. Wender-Ożegowska E, Zawiejska A, Michałowska-Wender G, et al. Metabolic syndrome in type 1 diabetes mellitus. Does it have any impact on the course of pregnancy? J Physiol Pharmacol. 2011; 62(5): 567–573. Erratum in: J Physiol Pharmacol 2012; 63(2): 205.
    PubMed
  15. Iciek R, Wender-Ozegowska E, Seremak-Mrozikiewicz A, et al. Leptin gene, leptin gene polymorphisms and body weight in pregnant women with diabetes mellitus type I. J Physiol Pharmacol. 2008; 59 Suppl 4: 19–31.
    PubMed
  16. Higgins M, Mc Auliffe F. A review of maternal and fetal growth factors in diabetic pregnancy. Curr Diabetes Rev. 2010; 6(2): 116–125.
    CrossRefPubMed
  17. Galazios G, Papazoglou D, Tsikouras P, et al. Vascular endothelial growth factor gene polymorphisms and pregnancy. J Matern Fetal Neonatal Med. 2009; 22(5): 371–378.
    CrossRefPubMed
  18. Torry DS, Wang HS, Wang TH, et al. Preeclampsia is associated with reduced serum levels of placenta growth factor. Am J Obstet Gynecol. 1998; 179(6 Pt 1): 1539–1544.
    CrossRefPubMed
  19. Reuvekamp A, Velsing-Aarts FV, Poulina IE, et al. Selective deficit of angiogenic growth factors characterises pregnancies complicated by pre-eclampsia. Br J Obstet Gynaecol. 1999; 106(10): 1019–1022.
    CrossRefPubMed
  20. Livingston JC, Chin R, Haddad B, et al. Reductions of vascular endothelial growth factor and placental growth factor concentrations in severe preeclampsia. Am J Obstet Gynecol. 2000; 183(6): 1554–1557.
    CrossRefPubMed
  21. Maynard SE, Min JY, Merchan J, et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest. 2003; 111(5): 649–658.
    CrossRefPubMed
  22. Taylor RN, Grimwood J, Taylor RS, et al. Longitudinal serum concentrations of placental growth factor: evidence for abnormal placental angiogenesis in pathologic pregnancies. Am J Obstet Gynecol. 2003; 188(1): 177–182.
    CrossRefPubMed
  23. Tidwell SC, Ho HN, Chiu WH, et al. Low maternal serum levels of placenta growth factor as an antecedent of clinical preeclampsia. Am J Obstet Gynecol. 2001; 184(6): 1267–1272.
    CrossRefPubMed
  24. Levine RJ, Maynard SE, Qian C, et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med. 2004; 350(7): 672–683.
    CrossRefPubMed
  25. Espinoza J, Romero R, Nien JK, et al. Identification of patients at risk for early onset and/or severe preeclampsia with the use of uterine artery Doppler velocimetry and placental growth factor. Am J Obstet Gynecol. 2007; 196(4): 326.e1–326.13.
    CrossRefPubMed
  26. Chappell LC, Duckworth S, Seed PT, et al. Diagnostic accuracy of placental growth factor in women with suspected preeclampsia: a prospective multicenter study. Circulation. 2013; 128(19): 2121–2131.
    CrossRefPubMed
  27. Spencer K, Heath V, El-Sheikhah A, et al. Ethnicity and the need for correction of biochemical and ultrasound markers of chromosomal anomalies in the first trimester: a study of Oriental, Asian and Afro-Caribbean populations. Prenat Diagn. 2005; 25(5): 365–369.
    CrossRefPubMed
  28. Spencer K, Bindra R, Cacho AM, et al. The impact of correcting for smoking status when screening for chromosomal anomalies using maternal serum biochemistry and fetal nuchal translucency thickness in the first trimester of pregnancy. Prenat Diagn. 2004; 24(3): 169–173.
    CrossRefPubMed
  29. Barton JR, Woelkers DA, Newman RB, et al. PETRA (Preeclampsia Triage by Rapid Assay) Trial. Placental growth factor predicts time to delivery in women with signs or symptoms of early preterm preeclampsia: a prospective multicenter study. Am J Obstet Gynecol. 2020; 222(3): 259.e1–259.e11.
    CrossRefPubMed
  30. Parchem JG, Brock CO, Chen HY, et al. Preeclampsia Triage by Rapid Assay Trial (PETRA) Investigators. Placental Growth Factor and the Risk of Adverse Neonatal and Maternal Outcomes. Obstet Gynecol. 2020; 135(3): 665–673.
    CrossRefPubMed
  31. Rouf F, Lloyd PG. Effect of Diabetes-Associated Metabolic Factors on Placental Growth Factor in Skeletal Muscle Cells. FASEB Journal. 2016; 30(S1): 766.6.
    CrossRef
  32. Gutaj P, Wender-Ozegowska E. Diagnosis and Management of IUGR in Pregnancy Complicated by Type 1 Diabetes Mellitus. Curr Diab Rep. 2016; 16(5): 39.
    CrossRefPubMed
  33. Loukovaara M, Leinonen P, Teramo K, et al. Concentration of cord serum placenta growth factor in normal and diabetic pregnancies. BJOG. 2005; 112(1): 75–79.
    CrossRefPubMed
  34. Khaliq A, Dunk C, Jiang J, et al. Hypoxia down‐regulates placenta growth factor, whereas fetal growth restriction up‐regulates placenta growth factor expression: molecular evidence for ‘placental hyperoxia’ in intrauterine growth restriction. Lab Invest. 1999; 79: 151–170.
    PubMed

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

 

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl